SRPT Q3 2017 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M

Gross Profit

$43M93.3% margin

Operating Income

-$46M-99.9% margin

Net Income

-$48M-103.9% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

+31.3%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$66M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$800M

Total Liabilities

$103M

Stockholders' Equity

$697M

Cash & Equivalents

$618M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$0	—
Gross Profit	$43M	-$34M	+227.7%
Operating Income	-$46M	-$57M	+18.8%
Net Income	-$48M	-$57M	+15.9%